Trial Information

Summary: A Randomized Phase II Study Of The Efficacy And Safety of Sunitinib Malate Schedule Four Weeks On And Two Weeks Off Versus Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RENAL EFFECT TRIAL)

Treatment to evaluate safety and effectiveness for Sunitinib in metastatic renal cancer

Patient Inclusion Criteria:

  • Untreated metastatic renal cell carcinoma

Patient Exclusion Criteria:

  • Prior treatment with Sunitinib

Contact:

Raquel Beauchamp, R.N., C.R.C., O.C.N., Clinical Research Coordinator
Gainesville Hematology/ Oncology Associates
1147 N. W. 64th Terrace
Gainesville, FL 32605
Telephone: 352-264-2540
Fax: 352-331-3802
Email:

Profile Page: Gainesville Hematology/ Oncology Associates, Gainesville, FL

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:33:26 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA